HC Wainwright Increases ASP Isotopes (NASDAQ:ASPI) Price Target to $5.50

ASP Isotopes (NASDAQ:ASPI) had its price objective increased by HC Wainwright from $5.25 to $5.50 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for ASP Isotopes’ FY2025 earnings at ($0.07) EPS.

ASP Isotopes Stock Performance

NASDAQ:ASPI opened at $3.04 on Wednesday. The firm has a market capitalization of $148.72 million, a PE ratio of -6.20 and a beta of 5.03. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. ASP Isotopes has a 1 year low of $0.28 and a 1 year high of $4.97. The firm’s fifty day simple moving average is $3.67 and its 200 day simple moving average is $2.38.

Insider Buying and Selling

In other ASP Isotopes news, Director Robert John Andrew Ryan bought 15,596 shares of the stock in a transaction on Monday, January 29th. The shares were purchased at an average price of $2.35 per share, with a total value of $36,650.60. Following the acquisition, the director now directly owns 537,055 shares of the company’s stock, valued at approximately $1,262,079.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 26.30% of the stock is owned by insiders.

Institutional Trading of ASP Isotopes

A number of hedge funds have recently bought and sold shares of ASPI. Virtu Financial LLC bought a new position in shares of ASP Isotopes during the 4th quarter worth about $26,000. Millennium Management LLC bought a new position in ASP Isotopes during the fourth quarter valued at about $49,000. HTLF Bank acquired a new position in ASP Isotopes in the 4th quarter valued at approximately $141,000. Citadel Advisors LLC bought a new stake in shares of ASP Isotopes in the 4th quarter worth approximately $187,000. Finally, Rathbones Group PLC acquired a new stake in shares of ASP Isotopes during the 4th quarter worth approximately $272,000. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.